[1] Hameetman L, Szuhai K, Yavas A, et al. The role of EXT1 in nonhereditary osteochondroma:Identification of homozygous deletions[J]. J Natl Cancer Inst, 2007, 99(5):396-406. [2] Karuppaiah K, Yu K, Lim J, et al. FGF signaling in the osteoprogenitor lineage non-autonomously regulates postnatal chondrocyte proliferation and skeletal growth[J]. Development, 2016, 143(10):1811-1822. [3] Zhou SR, Xie YL, Tang JZ, et al. FGFR3 deficiency causes multiple chondroma-like lesions by upregulating hedgehog signaling[J]. PLoS Genet, 2015, 11(6):e1005214. [4] Torlakovic EE. How to validate predictive immunohistochemistry testing in pathology?[J]. Arch Pathol Lab Med, 2019, 143(8):907. [5] 沈末伦, 朱凌, 王旭东.髁突骨软骨瘤的CT与MRI诊断价值比较[J]. 中国口腔颌面外科杂志, 2017, 15(2):147-152. [6] 凌彬, 王冰, 邵博, 等. 髁突骨软骨瘤的诊治及影像学分析[J]. 口腔医学研究, 2018, 34(3):302-306. [7] Lu C, Xie QY, He DM, et al. Stability of orthognathic surgery in the treatment of condylar osteochondroma combined with jaw deformity by CT measurements[J]. J Oral Maxillofac Surg, 2020, 78(8):1417.e1-1411417.e14. [8] Cao J, Shen SY, Liu ZX, et al. Evaluation of mandibular symmetry in patients with condylar osteochondroma who underwent intro-oral condylar resection and simultaneous bimaxillaryorthognathic surgery[J]. J Craniofac Surg, 2020, 31(5):1390-1394. [9] Ord RA, Warburton G, Caccamese JF. Osteochondroma of the condyle: Review of 8 cases[J]. Int J Oral Maxillofac Surg, 2010, 39(6):523-528. [10] Roychoudhury A, Bhatt K, Yadav R, et al. Review of osteochondroma of mandibular condyle and report of a case series[J]. J Oral Maxillofac Surg, 2011, 69(11):2815-2823. [11] Peroz I. Osteochondroma of the condyle:Case report with 15 years of follow-up[J]. Int J Oral MaxillofacSurg, 2016, 45(9):1120-1122. [12] Xu L, Xia J, Jiang H, et al. Mutation analysis of hereditary multiple exostoses in the Chinese[J]. Hum Genet, 1999, 105(1/2):45-50. [13] Zhou Q, Yang C, Chen MJ, et al. Detection of exostosinglycosyltransferase gene mutations in patients with non-hereditary osteochondromas of the mandibular condyle[J]. MolClinOncol, 2016, 5(3):295-299. [14] Stickens D, Brown D, Evans GA. EXT genes are differentially expressed in bone and cartilage during mouse embryogenesis[J]. DevDyn, 2000, 218(3):452-464. [15] Francannet C, Cohen-Tanugi A, le Merrer M, et al. Genotype-phenotype correlation in hereditary multiple exostoses[J]. J Med Genet, 2001, 38(7):430-434. [16] Pacifici M. The pathogenic roles of heparan sulfate deficiency in hereditary multiple exostoses[J]. Matrix Biol, 2018, 71/72:28-39. [17] Anower-E-Khuda MF, Matsumoto K, Habuchi H, et al. Glycosaminoglycans in the blood of hereditary multiple exostoses patients: Half reduction of heparan sulfate to chondroitin sulfate ratio and the possible diagnostic application[J]. Glycobiology, 2013, 23(7):865-876. [18] Kreuger J, Spillmann D, Li JP, et al. Interactions between heparan sulfate and proteins:The concept of specificity[J]. J Cell Biol, 2006, 174(3):323-327. [19] Toydemir RM, Brassington AE, Bayrak-Toydemir P, et al. A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome[J]. Am J Hum Genet, 2006, 79(5):935-941. [20] Talbot SG, Upton J, Rogers GF. Muenke syndrome associated with multiple osteochondromas[J]. J Craniofac Surg, 2012, 23(2):e115-e117. [21] Pacifici M. Hereditary multiple exostoses:New insights into pathogenesis, clinical complications, and potential treatments[J]. Curr Osteoporos Rep, 2017, 15(3):142-152. [22] Toledo AG, Sorrentino JT, Sandoval DR, et al. A systems view of the heparan sulfate interactome[J]. J Histochem Cytochem, 2021, 69(2):105-119. [23] 毕文敬, 江建冰. 硫酸乙酰肝素酶(HPSE)抑制剂的研究进展[J]. 中国药物化学杂志, 2022, 32(3):231-244. [24] 王奕, 王彦亮, 胡荣党. 基膜蛋白聚糖在骨缺损修复中的作用[J]. 国际口腔医学杂志, 2013, 40(5):691-694. [25] 周琴, 陈敏洁, 杨驰. 髁突骨软骨瘤患者EXT基因的突变检测[J]. 中国口腔颌面外科杂志, 2015, 13(6):521-524. |